NCT07079644Completed
Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
Real World Outcomes of Nivolumab + Relatlimab in Patients With Advanced Melanoma in the Flatiron Database
Source: ClinicalTrials.gov · Last updated 23 Jul 2025
Brief summary (registry, in English)
The purpose of this study is to investigate the real-world clinical outcomes of individuals that have been diagnosed with advanced melanoma who were treated with Nivolumab in combination with Relatlimab, Nivolumab in combination with Ipilimumab, immuno-oncology monotherapy or BRAF/MEK inhibitors therapy
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 678 (actual)
- First submitted
- 10 Jun 2025
- Start date
- 29 Nov 2024
- Primary completion date
- 31 Mar 2025
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Melanoma
- NCT number
- NCT07079644
What you commit to
- Study type: Observational
- Participants enrolled: 678
- From 29 Nov 2024 to the primary completion date, 31 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with diagnosis of other primary cancers prior to the index date
- Participants receiving medication in a clinical trial at any time prior to, on or after index date
Who the study is looking for
- Participants in the advanced melanoma cohort
- Participants included in the cohort by Flatiron criteria of: cutaneous melanoma with pathologic stages III or IV, either at initial diagnosis or via local or distant recurrence, and at least two clinic encounters evident in the database
- Participants receiving Nivolumab + Relatlimab between March 18, 2022 and September 30, 2024 or other therapies (Nivolumab + Ipilimumab, immunotherapy monotherapy, BRAF/MEK inhibitors) between March 18, 2022 and November 30, 2024 (or date of the most recent data cut off)
- Participants ≥18 years old on index date
- Participants with ≥1 month of medical data after the index date (inclusive), unless patient died within this period
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bristol Myers Squibb Coordinator of this site? Confirm its status | Princeton | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.